Kornimate/medical-research-clean huggingface dataset:
hemodynamics and vital organ function in intracerebral hemorrhage

Conditions: Balanced Anesthesia; Intracerebral Hemorrhage; Total Intravenous Anesthesia

Summary: spontaneous non-traumatic intracerebral hemorrhage (ich) is a common symptom in clinical practice and is the most serious among all types of stroke.recently, as a relatively mainstream and recognized interact2 (five well-known international studies in the cerebrovascular field: ims-iii, mr rescue, synthesis expansion, interact2, chance) studies have shown that in patients with standard systolic blood pressure early intensive antihypertensive therapy does not increase the incidence of death or serious adverse events. the above studies confirm the safety and efficacy of early potent depression.in 2017, anesthesiology published a meta analysis of intraoperative hypotension and blood pressure versus baseline fluctuations. the final outcome showed that 20% of blood pressure in the study was similar to map \<65 mmhg, regardless of the duration of the duration there will be postoperative myocardial and renal damage. ischemia is a very important cause of organ damage. myocardial injury is closely related to the level of mean arterial pressure, while ischemia and ischemic reperfusion injury are closely related to postoperative acute renal injury.there is no targeted guideline for ich perioperative blood pressure management, especially intraoperative blood pressure management, and no previous studies have studied most of the studies involving ich patients with conservative treatment, ich patients with surgical treatment there are few reports on blood pressure control during surgery.

the general anesthesia used in craniotomy, whether intravenous anesthesia or total intravenous anesthesia, have a certain degree of blood pressure and lead to a decline in blood pressure, the study aims to spontaneous cerebral hemorrhage this special and to observe the changes of hemodynamics and the changes of heart and kidney function in ich, and to explore the relationship between the anesthesia and the blood of ich. the range of volatility.

Eligibility criteria:
inclusion criteria: 1. age 18 years to90 years. 2. acute stroke symptoms caused by initial spontaneous intracerebral hemorrhage as determined by ct or mri blood: the screen area: 30-50ml; cerebellum parts:\> 10ml. 3. gcs score\> 5 points exclusion criteria: 1. ich is caused by other factors (anticoagulation associated with cerebral hemorrhage, arteriovenous malformations, tumors) 2. intracerebral hematoma is thought to be associated with trauma (simple intracerebral hemorrhage) 3. there are surgical contraindications. 4. history of ischemic stroke 5. acute spontaneous intracerebral hemorrhage before the presence of dementia or limb dysfunction (paralysis or aphasia. 6. preoperative combined with chronic kidney disease (standard for glomerular filtration rate below 60 ml · min-1 · 1.73 m2 or received dialysis). 7. anesthesia time shorter than 60 min or lack of relevant basic information. 8. while there is interference with the experimental results or follow-up of the disease (tumor, severe cardiovascular disease).
safety and efficacy study of foam otic cipro compared to a standard solution ( ciloxan - alcon labs ) to treat acute otitis externa

Conditions: Otitis Externa; Otorhinolaryngologic Diseases; Ear Diseases; Otitis

Summary: the purpose of this study is to assess the safety and efficacy of foam otic cipro, a novel medication developed to treat acute diffuse otitis externa of bacterial origin. the working hypothesis is that foam otic cipro is as effective as registered ear drops.

acute otitis externa (aoe) is defined as a diffuse inflammation of the external ear canal, which may also involve the pinna and/or the tympanic membrane. aoe is one of the most common infections encountered by otolaryngologists, pediatricians and family physicians. the reported annual incidence of aoe is between 1:100 and 1:250 in the general population with large seasonal and regional variations. diagnosis of aoe requires rapid onset (generally within 48 hours) of symptoms and signs of ear canal inflammation which includes: a) otalgia (often severe), itching or fullness, sometimes accompanied by reduced hearing or jaw pain; b) tenderness of the tragus and/or pinna; and c) diffuse ear canal edema with or without erythema, sometimes accompanied by ear discharge.

Eligibility criteria:
inclusion criteria: * aged 18 and older eligible to sign by themselves. * have a clinical diagnosis of acute otitis externa based on clinical observation and of presumed bacterial origin. * intact tympanic membrane * unilateral acute otitis externa exclusion criteria: * known allergy or sensitivity to ciprofloxacin or other quinolones. * clinical diagnosis of chronic suppurative otitis media (csom), acute otitis media (aom), involvement of middle ear effusion (mee). * patient has the non intact tympanic membrane. * patient has a serious underlying disease. * patients with known history of immune dysfunction/deficiency and those receiving immunosuppressive therapy. * patients with history of diabetes mellitus. * bilateral acute otitis externa. * patients with more than 80% of the ear canal occluded. * pregnant or lactating patients. * overt fungal acute otitis externa. * local ear canal abnormalities such as abscess, granulation or polyps. * congenital abnormalities of the external auditory canal or obstructive bony exostosis in the treated ear. * mastoid or other suppurative non-infectious ear disorder (e.g. cholesteatoma) in the treated ear. * seborrheic dermatitis or other dermatological conditions of the external auditory canal which would complicate evaluation. * current infection requiring systemic antimicrobial therapy. * current or previous use of topical or oral antibiotics (within 3 days) or long-acting antibiotics (within 7 days). * current enrollment in an investigational drug or device study or participation in such a study within 30 days of entry into this study.

Keywords: swimmer's ear ear drops ear foam otic foam ear infection ear pain ear inflammation
high protein atkin's complete (lacto) vegetarian diet (pacer) and weight loss

Conditions: Obesity

Summary: this study evaluates the effects "high protein atkin's complete (lacto) vegetarian diet (acronym; 'pacer' diet) on weight, body composition and metabolic profiles in obese asian indians subjects living in north india.

increasing the protein consumption promotes weight loss through several mechanisms. diets high in protein promote energy expenditure through increased postprandial thermogenesis, increase total daily expenditure and increase satiety as compared to carbohydrate. the present study aims to evaluate the effects "high protein atkin's complete (lacto) vegetarian diet (acronym; 'pacer' diet) on weight, body composition and metabolic profiles in obese asian indians subjects living in north india.

Eligibility criteria:
inclusion criteria * age 25 to 60 years * body mass index (bmi) ≥ 25 kg/m2 to 40 kg/m2 * subjects who have stable weight, i.e. who have not had more than ± 3 kg variation in their weight level in the 3 months prior to screening for this study. * absence of significant disease or clinically significant medical history or physical examination during screening in the view of the investigator. * subjects willing to provide written inform consent to participate in the study. exclusion criteria * body mass index (bmi) \> 40 kg/m2 * any patient taking/requiring drugs known to effect insulin resistance, lipids, vascular reactivity, during the intervention period would be excluded from the study * patients on any drugs that change the weight or in conditions where dietary protein supplementation is contraindicated * subjects who are consuming a high protein diet on randomization, to be excluded * acute infections or chronic debilitating diseases like tuberculosis, malignancy, hiv infection etc * any life threatening serious disorder of the liver, kidneys, heart, lungs or other organs * pregnancy \& lactation * patients having diagnosed with any of the following: * type 2 diabetes mellitus * cushing's disease * severe end organ damage * unwillingness to give written informed consent for participation in the study

Keywords: obesity abdominal adiposity high protein diet
metabolic health improvement program: effects of a workplace sugary beverages sales ban and motivational counseling

Conditions: Obesity, Abdominal; Insulin Sensitivity

Summary: the purpose of the study is to test the impact of a multilevel workplace intervention (hospital-wide sales ban on sugar-sweetened beverages (ssbs) and individual-level brief counseling) on employee health.

this double-randomized controlled trial of a multilevel workplace intervention that combines an employer-sponsored sales ban on sugar-sweetened beverages (ssbs) with brief counseling to support reduced consumption will test how well each intervention works alone, whether they work better in combination than separately, and whether or not changes in ssb cravings mediate these effects. sutter health worksites will be randomly assigned to either a control condition or to implement a sales ban on ssbs. within all sites, employees will be randomized to receive/not receive a brief counseling intervention focused on reducing ssb consumption. participants will complete self-report questionnaires, give blood samples, and provide measurements of waist circumference, height, and weight. these data will be analyzed to determine the effects of the interventions, both separately and in combination.

Eligibility criteria:
inclusion criteria: * full-time employee who works on campus at one of the sutter health participating sites * speaks and reads english * consumes three or more sugar-sweetened beverages (ssb) a week * agrees to participate in two fasting blood draws exclusion criteria: * pregnant
an open-label, single-dose study to evaluate safety, tolerability, and pharmacokinetics of brodalumab in pediatric subjects

Conditions: Psoriasis

Summary: an open-label, single-dose study to evaluate safety, tolerability, and pharmacokinetics of brodalumab in pediatric subjects

an open-label, single-dose study to evaluate safety, tolerability, and pharmacokinetics of brodalumab in pediatric subjects (6 to \< 18 years old) with severe plaque psoriasis

Eligibility criteria:
inclusion criteria: 1. subject's parent(s) or legally acceptable representative has provided informed consent, using an independent ethics committee (iec) or institutional review board (irb) approved informed consent form (icf), when the subject is legally too young to provide informed consent and the subject has provided written assent based on local regulations and/or guidelines prior to any study-specific activities/procedures being initiated, or when the subject has any kind of condition that, in the opinion of the investigator, may compromise the ability of the subject to give written informed consent. 2. males and females ages 6 to \<18 years of age, inclusive, at the time of screening 3. subjects must have up-to-date immunizations according to the relevant local country guideline. subjects must not be scheduled to be vaccinated while on study. 4. female subjects of childbearing potential must have a negative serum pregnancy test at screening and a negative serum or urine pregnancy test at baseline (day 1). a female of childbearing potential is defined as a female who is fertile, following menarche. exclusion criteria: 1. received conventional systemic therapies or phototherapy for treatment of psoriasis within the last 4 weeks. topical corticosteroids are allowed. 2. female subjects who have reached puberty and are sexually active and are unwilling to use acceptable methods of effective birth control for the duration of the study and continuing for 5 weeks after receiving the dose of study drug. acceptable methods of effective birth control include sexual abstinence (males and females); double barrier method (male condom with spermicide in combination with one female barrier method \[diaphragm, cervical cap, or contraceptive sponge)\]; or hormonal birth control; or intra-uterine device. 3. female subjects who are lactating/breastfeeding or who plan to breastfeed while on study through 5 weeks after receiving the dose of study drug. 4. female subjects with a positive pregnancy test. 5. female subjects who are pregnant or planning to become pregnant while on study through 5 weeks after receiving the dose of study drug.
patients with chronic obstructive pulmonary disease at altitude - effect of nocturnal oxygen on exercise performance

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Summary: the purpose of this study is to investigate the effect of nocturnal oxygen therapy during a stay at moderate altitude on exercise performance of patients with chronic obstructive lung disease.

patients with moderate to severe copd living below 800 m, will be recruited to participate in a randomized cross-over field trial evaluating the hypothesis that exercise capacity during a 2 day sojourn at moderate altitude is improved by nocturnal oxygen therapy via a nasal cannula. outcomes will be assessed during 2 days in zurich (490 m, low altitude baseline), and during 2 days at st. moritz salastrains (2048 m).

Eligibility criteria:
inclusion criteria: * chronic obstructive pulmonary disease (copd), gold grade 2-3 * residents at low altitude (\<800 m) exclusion criteria: * unstable condition, copd exacerbation * mild (gold 1) or very severe copd (gold 4) * requirement for oxygen therapy at low altitude residence * hypoventilation * pulmonary hypertension * more than mild or unstable cardiovascular disease * use of drugs that affect respiratory center drive * internal, neurologic or psychiatric disease that interfere with protocol compliance including current heavy smoking (\>20 cigarettes per day), inability to perform 6 min walk test. * previous intolerance to moderate altitude (\<2600m). * exposure to altitudes \>1500m for \>2 days within the last 4 weeks before the study. * pregnant or nursing patients

Keywords: airway disease bronchitis emphysema lung
establishment of optimal transfusion threshold during spine surgery

Conditions: Anemia; Spine Surgery

Summary: the purpose of this study is to determine whether a higher threshold for transfusion with red blood cells improves the tissue oxygenation.


Eligibility criteria:
inclusion criteria: * 18 years or older * patients undergoing spine surgery * be legally competent * read and understand danish exclusion criteria: * present malignant disease * previously apoplexia cerebri * known heart disease with functionality equivalent to nyha ii or ccs ii or worse

Keywords: anemia tissue oxygenation spine surgery
the effect of cognitive-behavioral intervention package on procedural pain and anxiety in children

Conditions: Procedural Anxiety; Procedural Pain

Summary: this study investigated the effect of cognitive-behavioral interventions package (cbip) on pain and anxiety related to peripheral venous cannulation (pvc) in children aged 7-12 years.

the international guide to pediatric anesthesia (good practice in postoperative and procedural pain) recommends pharmacological and nonpharmacological methods to effectively manage and prevent acute procedural pain in children. nonpharmacological methods alone or in combination with pharmacological methods help reduce pain, and therefore, have become popular especially in recent years. for pain management, nonpharmacological methods are easy to use, and cost- and time-effective methods with no side effects. studies have evaluated a large number of pharmacological and nonpharmacological interventions for procedural pain management in children. however, most of those interventions are not used by healthcare professionals because they are expensive, time-consuming or hard to use. therefore, easy-to-use, practical, non-invasive, cost-effective, and reusable nonpharmacological methods can be used especially in acute settings. cognitive-behavioral interventions, one of the non-pharmacological methods used to minimize pain and anxiety related to painful medical procedures in children are promising.

Eligibility criteria:
inclusion criteria: * being between the ages of 7 to 12 years * be literate * requiring peripheral venous cannulation procedure exclusion criteria: * had chronic diseases * had neuro-developmentally delayed * had visual, audio, or speech impairments * were hospital stay for treatment in the past three years * had a history of sedative, analgesic or narcotic use within 24 hours before procedure

Keywords: anxiety children procedural pain cognitive-behavioral interventions
effect of a nutritional support system for improving gross motor function in cerebral palsy

Conditions: Nutrition Disorder, Child; Gross Motor Development Delay; Neuro: Cerebral Palsy; Diet Modification; Probiotics

Summary: background: most patients with cerebral palsy (cp) are dependent on parents due to the spasticity and limitations in their gross motor function. additionally, many of them do not respond to physical therapy due to deterioration in their nutritional status, which is secondary to gastrointestinal disorders, parasitosis, dysbiosis and the catabolic state of the disease itself. evidence suggests that greater independence and better clinical response can be achieved by correcting the nutritional status. however, basic treatments only contemplate the calculation of energy requirements and do not consider important nutrients in particular, supplementation with glutamine, arginine, zinc, selenium, colecalciferol, nicotinic acid, spirulina, omega 3, ascorbic acid, vegetal protein or even probiotics. objective: to determine the effect of using a nutritional support system (nss) diet, supplements and probiotic on the gross motor function in children with cp with spastic diparesic and gross motor function classification system iii (gmfcs iii). material and methods: in an exploratory study with controlled clinical trial design, 30 patients were randomly assigned to receive: 1) dietary surveillance and conventional therapy (fg), 2) deworming and who diet (cg), or 3) deworming and the nss (ig). the patients were recruited from the children´s telethon rehabilitation center (crit) in tlalnepantla estado de méxico. males and females aged 4-12 years were included with cp and spastic diparesic gmfcs iii, who had a full-time caregiver and whose parents agreed to participate. they were studied for thirteen weeks. gross motor function was evaluated at baseline and at 7 and 13 weeks after therapy using the gmfm scale.


Eligibility criteria:
inclusion criteria: * patients with cp with spastic diparesia and gmfcs iii * re-entry * presence and support of a full-time caregiver * to tolerate oral feeding * parents or guardians agree in writing to participate in the project * patients treated at the crit of tlalnepantla edo. mex * that the children, in the case of being able to write, accept in writing to participate in the project exclusion criteria: * presence of any other catabolic disease, which further increases the risk of malnutrition (renal, cardiovascular, pulmonary, hepatic, immunological) * have had infectious problems or have received antibiotic treatment 15 days prior to the start of the study. * have received botulinum toxin therapy in the last 4 months * muscle relaxants in the last 6 months * severe gastroesophageal reflux * patients with any type of surgery performed with a period shorter than 9 months * that can walk by themselves
synbiotics interventions for managing cirrhosis and its complications

Conditions: Cirrhosis, Liver; Metagonimiasis

Summary: background liver cirrhosis is commonly accompanied by intestinal dysbiosis and metabolic defects. many clinical trials have shown microbiota-targeting strategies represent promising interventions for managing cirrhosis and its complications. however, the influences of the intestinal metagenomes and metabolic profiles of patients have not been fully elucidated. methods administered lactulose, clostridium butyricum, and bifidobacterium longum infantis as a synbiotic and used shotgun metagenomics and non-targeted metabolomics to characterize the results.


Eligibility criteria:
inclusion criteria: * ① hepatitis b cirrhosis was diagnosed by clinical biochemistry and imaging. * ctp rating is a-b. * there was a previous liver cirrhosis complication, including ascites, spontaneous peritonitis, massive gastrointestinal bleeding, liver coma, etc. * over 18 years old. ⑤ under 90 years old. * the patient or family member signs the informed consent form. exclusion criteria: * ① the ctp of liver cirrhosis was evaluated as grade c. * other types of cirrhosis such as primary biliary cirrhosis. * pregnancy status. ④ have a history of diabetes, renal insufficiency, gastrointestinal surgery, etc. * antibiotics, ppi preparations and microecological preparations (including yogurt) have been used in the past 8 weeks. * have a history of narcotic drug abuse, drug abuse, or mental illness. ⑦ patients and their families do not agree to sign the informed consent form. ⑧ under 18 years old or over 90 years old.

Keywords: cirrhosis, liver synbiotics
effect of pp in patients with ultra-low vt

Conditions: Acute Respiratory Distress Syndrome; Prone Position; Tidal Volume

Summary: acute respiratory distress syndrome (ards) is a heterogeneous syndrome with similar clinicopathological feathers caused by different etiologies. respiratory supportive strategies is the main ards management, and the guidelines recommend low tidal volume to improve clinical outcomes. to be note, overdistension can still occur even if using a tidal volume as low as 6 ml/kg, given the heterogeneous nature of the syndrome. therefore, adjusting tidal volume level to less than 6ml/kg may reduce ventilator-induced lung injury (vili) and thus improve outcomes, especially in patients with severe lung injury. prone position is also an important management in severe ards. prone position can improve ventilation-perfusion (v/q) matching and reduce the risk of vili by recruiting dorsal collapsed alveoli. meanwhile, prone position has also been shown to improve hemodynamics. recent studies have showed that prone position did not reduce duration of venovenous extracorporeal membrane oxygenation (vv-ecmo) and 90-day mortality in patients with ards who receive vv-ecmo with ultra-low tidal volume ventilation. therefore, the effect of pp on ventilation and lung blood flow in ards patients treated with vv-ecmo wiht ultra-low tidal volume ventilation remains unclear.


Eligibility criteria:
inclusion criteria: * adult patients were enrolled if they were undergoing invasive mechanical ventilation and were supported by vv-ecmo for less than 48 hours exclusion criteria: * younger than 18 years old * contraindications for prone position ventilation * past chronic respiratory diseases (long-term family oxygen therapy for chronic * respiratory diseases such as pulmonary fibrosis or copd) * new york heart association class above ii * contraindications to the use of eit (e.g., presence of pacemaker or chest surgical wounds dressing) or prone position (as decided by the attending physician) * severe hemodynamic instability * gave written or witnessed verbal informed consent